• Explore /
  • Poster
  • / A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).

A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).

Abstract Poster

Authors

null

Yi Zhang

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Yi Zhang , Hu Zhou , Junling Zhuang , Aili He , Yarong Li , Linhua Yang , Xin Du , Sujun Gao , Guangsheng He , Mei Hong , Qian Jiang , Zhongxing Jiang , Kai Sun , Lingling Yue , Cuiping Zheng , Zeping Zhou , Zhi-Jian Xiao , Jie Jin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04617028

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7015)

DOI

10.1200/JCO.2023.41.16_suppl.7015

Abstract #

7015

Poster Bd #

145

Abstract Disclosures

Similar Posters

First Author: Yi Zhang

First Author: Aaron Thomas Gerds

First Author: Aaron Thomas Gerds

First Author: Abdulraheem Yacoub